You win a hospital value analysis committee by making the decision easy to defend, not by making it exciting. The surgeon's yes gets your device on the agenda. It doesn't get it approved, because the committee isn't really asking whether the device is good. It's asking whether each person at the table can explain the approval later, to people whose questions they can't predict.
That's a different question than the one most device reps are trained to answer. Field training is built around the physician champion: earn the surgeon's trust, get the product in their hands, let their enthusiasm open doors. It works right up until the value analysis committee. Then a rep who did everything right watches a deal stall for months, or die in a room they were never invited into.
Here's why the VAC is a different buyer, what's going on in the heads of the people around that table, and what your reps should bring instead of more conviction.
Why This Is Harder Than It Looks
Start with the uncomfortable part. The committee exists because of physician preference. Physician preference items account for anywhere from 40 to 60 percent of a hospital's supply spending, according to a 2018 study by Lawton Burns and colleagues. Value analysis grew up as the hospital's answer to that cost. So when your submission arrives framed as "one of our surgeons wants this," you've described the exact kind of request the committee was built to slow down.
Second, your champion probably isn't in the room the way you think. In a 2024 GHX and AHVAP survey of 1,635 U.S. healthcare leaders, 85 percent reported less than strong physician engagement in their value analysis process. The surgeon who loves your device may never speak to the people deciding on it.
Third, a yes from the committee isn't the finish line. In a 2023 IQVIA survey of VAC members, only about one third of products were approved for broad use across the hospital even after VAC approval. In academic hospitals, 67 percent of products reviewed by a department-level committee had to go through another committee with wider authority. Your rep isn't selling one decision. They're selling a series of them, to people with very different jobs.
Who Actually Sits on a Value Analysis Committee
Membership varies, but committees are often large, commonly 12 to 24 people, according to medtech strategist Maria Shepherd's analysis in Medical Product Outsourcing. Supply chain most often leads, followed by physicians. Each seat needs something different from you.
| Seat at the Table | What They Answer For | What They Need From You |
|---|---|---|
| Supply chain or value analysis lead | Savings targets, contract compliance, vendor count | Total cost of ownership versus the current product, GPO contract status, a clear price |
| Finance | Cost per case and budget | Cost per procedure, reimbursement impact, who absorbs which costs |
| Nursing and OR leadership | Staff time, workflow, patient safety | Training hours, in-service plan, setup changes, support on nights and weekends |
| Quality and risk | Adverse events and compliance exposure | Safety data, recall history, how outcomes will be tracked after go-live |
| Physician members | Clinical standards across the department | Comparative evidence, not one surgeon's experience |
What's Actually Going On
Two well-documented findings explain why a committee behaves so differently from the surgeon who already said yes.
The brain treats "we don't know" as its own threat
In 1961, economist Daniel Ellsberg showed that people prefer a bet with known odds over one with unknown odds, even when the unknown bet could be better. That's ambiguity aversion. In 2005, Ming Hsu, Colin Camerer and colleagues at Caltech and the University of Iowa mapped it in the brain. Writing in Science, they reported that as choices became more ambiguous, activity rose in the amygdala and orbitofrontal cortex and fell in the striatum, a region tied to expected reward. Patients with orbitofrontal damage didn't show the usual caution. They were far more willing to take gambles with unknown odds.
The brain doesn't just weigh what could go wrong. It separately flags what it can't estimate. Your competitor's device has known odds: a known complication profile, a known price, a known training load. Yours might be better. But "might" with unknown odds lands heavier than a known downside. Every blank in your submission, from cost after introductory pricing to who trains the night shift, adds to that weight.
Every member answers to an audience they can't predict
Psychologists Jennifer Lerner and Philip Tetlock reviewed decades of accountability research in Psychological Bulletin in 1999. When people learn before they decide that they'll have to justify the choice to an audience whose views they don't know, they shift into preemptive self-criticism. They think harder, look for flaws, and try to anticipate every objection they might face. When they know what the audience wants, they drift toward it. When they've already committed publicly, they spend their effort defending the position they took.
That's a near-perfect description of a VAC member. In the same GHX and AHVAP survey, 83 percent of respondents said value analysis savings get reported to the head of supply chain, and 70 percent said they go to the CFO. The nurse manager answers to her staff and the CNO. The physician member answers to colleagues whose device request was turned down last quarter. None of them knows which question is coming, so they're all hunting for the weak spot before someone else finds it.
The committee isn't asking, "Is this a good device?" It's asking, "Can I defend this if someone asks me why?"
Why Surgeon Enthusiasm Reads as a Risk Signal
Put those two findings together and the problem with the champion strategy gets clear. A passionate surgeon brings conviction, not evidence. To a group that's busy pre-loading objections, conviction raises questions it can't answer. Is this about outcomes, or about preference and familiarity? Will other surgeons adopt it, or are we adding a second product for one person? What happens to cost when the next surgeon wants their own version?
To a committee, a surgeon's enthusiasm is information about the surgeon. It isn't information about the device. David Berkowitz of ECRI made a version of this point to MD+DI: device companies often make the mistake of focusing only on clinicians and their reported benefits. To replace a product already in use, he said, the hospital needs a clear difference backed by documented evidence, not anecdote.
The instinct when a VAC stalls is to escalate. Bring the surgeon to present. Bring more passion. That adds pressure without removing any ambiguity. And once members have voiced doubts out loud, the accountability research suggests pushing harder tends to make them defend those doubts rather than revisit them.
What to Do About It
The goal shifts from persuading the committee to making approval easy to justify.
1. Map the accountabilities before you build the submission
Ask the value analysis coordinator who chairs the committee, what the request form asks for, and how products get evaluated. The chair matters. Shepherd notes that supply chain or finance chairs tend to put price first, while clinical chairs tend to put outcomes first. Then, for each seat, write down who that person answers to and the question they'd least like to be asked.
2. Turn your surgeon from advocate into evidence source
Don't ask the surgeon to sell. Ask them to document: the specific clinical problem with the current product, case outcomes, OR time, anything measurable. Then find a second physician. A request from a department reads very differently from one surgeon's preference.
3. Close every cost and workflow gap in writing
Give total cost of ownership against the current product, not unit price. Spell out reimbursement impact, training hours per nurse, the in-service schedule, and who covers cases on nights and weekends. Confirm the contract status with the hospital's GPO. Each gap you leave is a bet with unknown odds, and the committee will price it accordingly.
4. Offer a bounded trial with success criteria the committee sets
A trial turns unknown odds into known ones. Propose the scope, the timeline, and the exit plan, then let the committee define what success means. Many products face a trial period anyway. Better to design it than be handed one.
5. Write the justification they'll have to give
Hand the committee a one-page summary written the way a member would present it upward: what was approved, why, the cost impact, and how the risk is contained. If a supply chain director could read it word for word to the CFO, you've done the job.
When This Doesn't Work
Sometimes the device really isn't different enough. When products are functionally equivalent, Berkowitz noted, the decision moves to price. No amount of framing fixes a missing clinical difference. Find the real one, or compete honestly on contract terms.
Sometimes the committee has already said no. Don't relitigate. Ask what would need to be true to bring it back, then go build that.
And sometimes the submission is fine but the conversations aren't. If your reps can't hold a calm, specific conversation with a supply chain director or an OR nurse manager, and slide back into a clinical pitch the moment they're challenged, that's a skill gap, not a paperwork gap. As we wrote in our piece on HCP access, access usually isn't the problem. The conversation is.
What This Means for Sales Leaders
Your deal reviews probably ask, "Is the surgeon on board?" Keep asking it. Then add a second question: "Who on the committee has to defend this, to whom, and what are we giving them to do it?"
Winning a VAC takes a different skill than winning a surgeon. Reps have to read what a non-clinical stakeholder is accountable for, lower the sense of threat in a room they don't control, and talk in that person's terms. Jeff Bloomfield, Braintrust's founder and the author of NeuroSelling, built the NeuroSelling methodology on the idea that buyers process trust before they process data. For a value analysis committee, trust mostly looks like one thing: no surprises.
It's also why so many device deals that look healthy end in no decision at all. Unresolved ambiguity rarely gets a firm no. It gets tabled. If you lead a device team, our life sciences work shows how we approach it.
If your team keeps winning surgeons and losing committees, it's worth a conversation. Start a Conversation with our team.
